The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders
| dc.contributor.advisor | Joska, John | |
| dc.contributor.advisor | Combrinck, Marc | |
| dc.contributor.advisor | Naude, Pieter | |
| dc.contributor.author | Groenewald, Engelina | |
| dc.date.accessioned | 2020-02-25T09:07:29Z | |
| dc.date.available | 2020-02-25T09:07:29Z | |
| dc.date.issued | 2019 | |
| dc.date.updated | 2020-02-25T06:22:14Z | |
| dc.description.abstract | There are as yet no ideal biomarkers of HIV-associated neurocognitive disorders. As astrocytosis is a feature of HIV encephalitis, the marker S100β may hold promise as a biomarker of HAND. We explored associations between S100β and neurocognition in individuals with HIV in Cape Town, South Africa, before and after antiretroviral therapy (ART) was initiated. The S100β levels in the cerebrospinal fluid (CSF) of forty-six participants with HIV, but not yet on antiretroviral therapy, was quantified using an enzyme-linked immunoassay (ELISA). A battery of cognitive tests was performed and the global deficit score (GDS) was calculated. In twenty of these patients, the S100β analysis and the cognitive tests were repeated approximately six months after the initiation of ART. There was no significant association between cerebrospinal fluid S100β and GDS at baseline (r= -0.070; p= 0.66) or after six months of ART (r= 0.16; p= 0.52). Cerebrospinal fluid S100β levels at baseline did not predict a change in neurocognition on ART (B(SE) = 0.001, (0.001), β=0.025, p=0.85). S100β in the cerebrospinal fluid may not adequately reflect neurocognitive impairment in individuals with HIV. Our results further demonstrate that CSF S100β levels are not affected by ART, indicating persistent neuroinflammation. | |
| dc.identifier.apacitation | Groenewald, E. (2019). <i>The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders</i>. (). ,Faculty of Health Sciences ,Department of Psychiatry and Mental Health. Retrieved from http://hdl.handle.net/11427/31290 | en_ZA |
| dc.identifier.chicagocitation | Groenewald, Engelina. <i>"The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders."</i> ., ,Faculty of Health Sciences ,Department of Psychiatry and Mental Health, 2019. http://hdl.handle.net/11427/31290 | en_ZA |
| dc.identifier.citation | Groenewald, E. 2019. The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders. | en_ZA |
| dc.identifier.ris | TY - Thesis / Dissertation AU - Groenewald, Engelina AB - There are as yet no ideal biomarkers of HIV-associated neurocognitive disorders. As astrocytosis is a feature of HIV encephalitis, the marker S100β may hold promise as a biomarker of HAND. We explored associations between S100β and neurocognition in individuals with HIV in Cape Town, South Africa, before and after antiretroviral therapy (ART) was initiated. The S100β levels in the cerebrospinal fluid (CSF) of forty-six participants with HIV, but not yet on antiretroviral therapy, was quantified using an enzyme-linked immunoassay (ELISA). A battery of cognitive tests was performed and the global deficit score (GDS) was calculated. In twenty of these patients, the S100β analysis and the cognitive tests were repeated approximately six months after the initiation of ART. There was no significant association between cerebrospinal fluid S100β and GDS at baseline (r= -0.070; p= 0.66) or after six months of ART (r= 0.16; p= 0.52). Cerebrospinal fluid S100β levels at baseline did not predict a change in neurocognition on ART (B(SE) = 0.001, (0.001), β=0.025, p=0.85). S100β in the cerebrospinal fluid may not adequately reflect neurocognitive impairment in individuals with HIV. Our results further demonstrate that CSF S100β levels are not affected by ART, indicating persistent neuroinflammation. DA - 2019 DB - OpenUCT DP - University of Cape Town KW - mental health LK - https://open.uct.ac.za PY - 2019 T1 - The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders TI - The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders UR - http://hdl.handle.net/11427/31290 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/31290 | |
| dc.identifier.vancouvercitation | Groenewald E. The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders. []. ,Faculty of Health Sciences ,Department of Psychiatry and Mental Health, 2019 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/31290 | en_ZA |
| dc.language.rfc3066 | eng | |
| dc.publisher.department | Department of Psychiatry and Mental Health | |
| dc.publisher.faculty | Faculty of Health Sciences | |
| dc.subject | mental health | |
| dc.title | The role of the astrocytic marker S100B in HIV-associated neurocognitive disorders | |
| dc.type | Master Thesis | |
| dc.type.qualificationlevel | Masters | |
| dc.type.qualificationname | MPhil |